Package Leaflet: Information for the Patient
Ofev 25mg Soft Capsules
nintedanib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Ofev contains the active substance nintedanib, a medicine that belongs to the class of drugs known as tyrosine kinase inhibitors, and is used to treat the following diseases:
Idiopathic pulmonary fibrosis (IPF) in adults
IPF is a disease that causes thickening, hardening, and scarring of the tissue in your lungs over time. As a result, the scarring reduces the ability to transfer oxygen from the lungs to the bloodstream, making it difficult to breathe deeply. Ofev helps to reduce the occurrence of further scarring and hardening of the lungs.
Other chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype in adults
In addition to IPF, there are other diseases in which the tissue in your lungs becomes thickened, hardened, and scarred over time (pulmonary fibrosis) and continues to worsen (progressive phenotype). Some examples of these diseases are hypersensitivity pneumonitis, autoimmune ILD (such as ILD associated with rheumatoid arthritis), idiopathic nonspecific interstitial pneumonia, idiopathic unclassifiable interstitial pneumonia, and other ILD. Ofev helps to reduce the occurrence of further scarring and hardening of the lungs.
Fibrosing interstitial lung diseases (ILD) in children and adolescents from 6 to 17 years of age
Pulmonary fibrosis can occur in patients with childhood interstitial lung disease. In this case, the tissue in the lungs of children and adolescents becomes thickened, hardened, and scarred over time. Ofev helps to reduce the occurrence of further scarring and hardening of the lungs.
Interstitial lung disease associated with systemic sclerosis (SSc-ILD) in adults, adolescents, and children from 6 years of age and older
Systemic sclerosis (SSc), also known as scleroderma (and juvenile systemic sclerosis in children and adolescents), is a rare chronic autoimmune disease that affects the connective tissue in many parts of the body. SSc causes fibrosis (scarring and hardening) of the skin and other internal organs, such as the lungs. When the lungs are affected by fibrosis, it is called interstitial lung disease (ILD) and the disease is called SSc-ILD. The fibrosis in the lungs reduces the ability to transfer oxygen to the bloodstream and reduces the ability to breathe. Ofev helps to reduce the occurrence of further scarring and hardening of the lungs.
Do not take Ofev
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Ofev
Based on this information, your doctor may perform some blood tests, for example, to check your liver function. Your doctor will discuss the results of these tests with you to decide if you can take Ofev.
Tell your doctor immediately while you are taking this medicine
Children and adolescents
Children under 6 years of age must not take Ofev.
Your doctor may perform regular dental checks at least every 6 months until the completion of tooth development and monitor your growth once a year (bone imaging study) while you are taking this medicine.
Other medicines and Ofev
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including herbal medicines and medicines obtained without a prescription.
Ofev may interact with other medicines. The following medicines may increase the levels of nintedanib in your blood and, therefore, increase the risk of side effects (see section 4, "Possible side effects"):
The following medicines are examples that may decrease the levels of nintedanib in your blood and, therefore, reduce the effectiveness of Ofev:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take this medicine during pregnancy, as it may harm the fetus and cause birth defects.
A pregnancy test must be performed to ensure you are not pregnant before starting treatment with Ofev. Talk to your doctor.
Contraception
Breastfeeding
Do not breastfeed your baby while taking Ofev, as it may harm the baby.
Driving and using machines
Ofev has a minor influence on the ability to drive and use machines. Do not drive or use machines if you feel dizzy.
Ofev contains soy lecithin
If you are allergic to soy or peanuts, do not take this medicine (see section 2, "Do not take Ofev").
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Take the capsules twice a day, with approximately 12 hours in between, and at about the same time each day; for example, one capsule in the morning and one capsule in the evening. This will ensure that you maintain a constant level of nintedanib in your blood. Swallow the capsules whole with water, without chewing them. It is recommended to take the capsules with food, i.e., during meals or immediately before or after meals. Do not open or break the capsule (see section 5, "Storage of Ofev").
To make it easier to swallow the capsules, you can take them with a small amount (one teaspoon) of a soft cold or room-temperature food, such as apple sauce or chocolate pudding. Swallow the capsules immediately and do not chew them to ensure they remain intact.
Adults
The recommended dose is one 150 mg capsule twice a day (a total of 300 mg per day).
Do not take more than the recommended dose of two Ofev 150 mg capsules per day.
If you do not tolerate the recommended dose of two Ofev 150 mg capsules per day (see possible side effects in section 4), your doctor may reduce your daily dose of Ofev. Do not reduce the dose or stop treatment yourself without consulting your doctor first.
Your doctor may reduce the recommended dose to 100 mg twice a day (a total of 200 mg per day). In this case, your doctor will prescribe Ofev 100 mg capsules for your treatment. Do not take more than the recommended dose of two Ofev 100 mg capsules per day if your daily dose has been reduced to 200 mg per day.
Use in children and adolescents
The recommended dose depends on the patient's weight.
Tell your doctor if the patient's weight is below 13.5 kg at any time during treatment.
Tell your doctor if you have liver problems.
Your doctor will determine the correct dose. Your doctor may adjust the dose during the course of treatment.
If you do not tolerate the recommended daily dose of Ofev capsules (see possible side effects in section 4), your doctor may reduce the daily dose of Ofev.
Do not reduce the dose or stop treatment yourself without consulting your doctor first.
Dosing based on weight for Ofev capsules in children and adolescents:
Weight range in kilograms (kg) | Ofev dose in milligrams (mg) |
13.5-22.9 kg | 50 mg (two 25 mg capsules) twice a day |
23.0-33.4 kg | 75 mg (three 25 mg capsules) twice a day |
33.5-57.4 kg | 100 mg (one 100 mg capsule or four 25 mg capsules) twice a day |
57.5 kg or more | 150 mg (one 150 mg capsule or six 25 mg capsules) twice a day |
If you take more Ofev than you should
Contact your doctor or pharmacist immediately.
If you forget to take Ofev
Do not take two capsules together if you have missed your previous dose. You should take your next dose of Ofev at the next scheduled time and as recommended by your doctor or pharmacist.
If you stop taking Ofev
Do not stop taking Ofev without talking to your doctor first. It is important to take this medicine every day while your doctor prescribes it.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
You should pay special attention if you experience the following adverse effects during treatment with Ofev:
Diarrhea(very frequent, may affect more than 1 in 10 people):
Diarrhea can cause dehydration: a loss of important fluids and salts from the body (electrolytes, such as sodium or potassium). If you experience the first symptoms of diarrhea, drink plenty of fluids and consult your doctor immediately. Start appropriate anti-diarrheal treatment as soon as possible, for example, by taking loperamide.
The following adverse effects have also been observed during treatment with this medicine.
Consult your doctor if you experience any type of adverse effect.
Idiopathic Pulmonary Fibrosis (IPF)
Very frequent adverse effects (may affect more than 1 in 10 people)
Frequent adverse effects (may affect up to 1 in 10 people)
Uncommon adverse effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Other Chronic Fibrosing Interstitial Lung Diseases (ILDs)
Very frequent adverse effects (may affect more than 1 in 10 people)
Frequent adverse effects (may affect up to 1 in 10 people)
Uncommon adverse effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Very frequent adverse effects (may affect more than 1 in 10 people)
Frequent adverse effects (may affect up to 1 in 10 people)
Uncommon adverse effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Chronic Fibrosing Interstitial Lung Diseases (ILDs) in Children and Adolescents
Adverse effects in children and adolescents were similar to those in adult patients.
Report to your doctor if you experience any type of adverse effect.
Reporting of Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the carton, blister, or bottle. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Blister: Store in the original packaging to protect from moisture.
Bottle: Keep the bottle tightly closed to protect from moisture.
Do not use this medicine if you notice that the blister containing the capsules is open or that a capsule is broken.
If you come into contact with the contents of the capsule, wash your hands immediately with plenty of water (see section 3, "How to take Ofev").
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Ofev Composition
Capsule contents: | medium-chain triglycerides, hard fat, soy lecithin (E322) (see section 2, "Do not take Ofev") |
Capsule shell: | gelatin, glycerol (85%), titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172) |
Printing ink: | shellac, black iron oxide (E172), propylene glycol (E1520) |
Product Appearance and Package Contents
Ofev 25 mg capsules are soft gelatin capsules, oval, opaque, and orange in color (approximately 8 × 5 mm), with black printing on one side with the number "25".
There are four package sizes for Ofev 25 mg capsules:
Not all package sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
You can obtain more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 5 2595942 |
Luxembourg/Luxemburg Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | |
Ceská republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Magyarország Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Tel: +36 1 299 89 00 |
Danmark Boehringer Ingelheim Danmark A/S Tlf.: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Deutschland Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Nederland Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8000 | Norge Boehringer Ingelheim Danmark Norwegian branch Tlf: +47 66 76 13 00 |
Ελλáδα Boehringer Ingelheim Ελλáς Μονοπρóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Österreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
España Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Polska Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | România Boehringer Ingelheim RCV GmbH & Co KG Viena – Sucursala Bucuresti Tel: +40 21 302 2800 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana Tel: +386 1 586 40 00 |
Ísland Vistor ehf. Sími: +354 535 7000 | Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizacná zložka Tel: +421 2 5810 1211 |
Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Κúπρος Boehringer Ingelheim Ελλáς Μονοπρóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas filiale Tel: +371 67 240 011 |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.